➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Baxter
Johnson and Johnson
Express Scripts
Moodys

Last Updated: January 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Ibudilast

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Ibudilast?

Ibudilast is an investigational drug.

There have been 19 clinical trials for Ibudilast. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2020.

The most common disease conditions in clinical trials are Sclerosis, Motor Neuron Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are MediciNova, University of California, Los Angeles, and National Institute on Drug Abuse (NIDA).

There are seven hundred and thirty-six US patents protecting this investigational drug and seven international patents.

Recent Clinical Trials for Ibudilast
TitleSponsorPhase
Regeneration in Cervical Degenerative MyelopathyCambridge University Hospitals NHS Foundation TrustPhase 3
Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDSMediciNovaPhase 2
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSMediciNovaPhase 2/Phase 3

See all Ibudilast clinical trials

Clinical Trial Summary for Ibudilast

Top disease conditions for Ibudilast
Top clinical trial sponsors for Ibudilast

See all Ibudilast clinical trials

US Patents for Ibudilast

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ibudilast   Start Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Ibudilast   Start Trial Therapeutic approaches for treating Parkinson's disease Pharnext (Issy les Moulineaux, FR)   Start Trial
Ibudilast   Start Trial Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells Selecta Biosciences, Inc. (Watertown, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Baxter
Johnson and Johnson
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.